Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QAX576 in Asthma Patients

NCT00940160 | Completed Phase 1

• 1 other identifier: CQAX576A2107
• Study Type: interventional
• Target: 30
• Locations: 2 countries
• Sites: 3

Brief Summary

This study is designed to investigate the safety and tolerability of multiple doses of QAX576 in controlled or partially controlled asthma patients.

Conditions

Asthma

Keywords

Asthma

Outcome Measures

Primary Outcomes (1)

• Measure: Assessing and comparing the safety and tolerability of multiple doses of QAX576 in controlled and partially controlled asthma patients.

  120 Days

Secondary Outcomes (2)

• Assessing the pharmacokinetics of multiple doses of QAX576 in asthmatics

  120 Days

• Assessing the effect of QAX576 on asthma control using assessments such as exhaled NO, FEV1 variability data captures by PIKO-1 home monitoring device and the extent of inhaled salbutamol use as rescue medication.

  120 Days

Study Arms (4)

QAX576 1 mg/kg

ACTIVE COMPARATOR

Drug: QAX576

QAX576 3 mg/kg

ACTIVE COMPARATOR

Drug: QAX576

QAX576 10 mg/kg

ACTIVE COMPARATOR

Drug: QAX576

Placebo

PLACEBO COMPARATOR

Drug: Placebo

Interventions

QAX576 DRUG

QAX576 1 mg/kg

Placebo DRUG

Placebo

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Non-smoking male and female subjects age 18 to 65 years, inclusive; with controlled or partially controlled asthma who are otherwise healthy as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening. Female subjects are allowed to participate in this study if they are postmenopausal or surgically sterilized.
• Controlled or partially controlled asthma as defined in GINA 2007.
• At Screening, and Baseline, vital signs (systolic and diastolic blood pressure and pulse rate) will be assessed after the subject has rested for at least three (3) minutes.
• Female subjects must be post-menopausal as confirmed by FSH ≥ 40, or have been surgically sterilized at least 6 months prior to screening.
• Subjects must have a body mass index (BMI) within the range of 18 to 30 kg/m2.
• Male subjects must be using two methods of contraception, i.e., spermicidal gel plus condom, for the entire duration of the study, up to Study Completion visit, and refrain from fathering a child in the six (6) months after study completion

You may not qualify if:

• Smokers (use of tobacco products in the previous 3 months).
• Use of any prescription drugs other than stable (4 weeks) use of hormone replacement or thyroid replacement within four (4) weeks prior to dosing (other than medication required for treatment of asthma).
• Use of any over the counter (OTC) medication within forty eight (48) hours prior to dosing.
• Use of oral steroids within 12 weeks prior to dosing.
• Patients who have received an investigational drug in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulations, and for any other limitation of participation based on local regulations.
• Any immunotherapy with systemic biologics as a treatment therapy or during a clinical study with in the last 6 months.
• Any immunotherapy with subcutaneous injections for allergy (allergy shots), within 3 months.
• Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing, or longer if required by local regulation.
• Patients suffering from hay fever at screening or likely to require treatment during the study.
• History of chronic respiratory disease other than asthma or chronic allergic rhinitis.
• Hospitalization for asthma in the last year.
• History of intubation/assisted ventilation for asthma in the last 5 years.
• History of autonomic dysfunction (e.g. history of fainting, orthostatic hypotension).
• History or presence of any surgical or medical condition or clinically significant abnormal laboratory findings, which, in the opinion of the investigator, may jeopardize the subject in case of participation in the study.
• History of drug or alcohol abuse within the 12 months prior to dosing or evidence of such abuse as indicated by the laboratory assays conducted during the screening or baseline evaluations.

Sponsors & Collaborators

• Novartis Pharmaceuticals: lead

Study Sites (3)

Novartis Investigator Site

Moscow, Russia

Location

Novartis Investigator Site

Saint Petersburg, Russia

Location

Novartis Investigator Site

Manchester, United Kingdom

Location

Related Links

• Results for CQAX576A2107 can be found on the Novartis Clinical Trial Results Website

MeSH Terms

Conditions

Asthma

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Officials

• Novartis Pharmaceuticals

  Novartis Pharmaceuticals

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: July 14, 2009
• First Posted: July 15, 2009
• Study Start: July 1, 2009
• Primary Completion: January 1, 2010
• Last Updated: December 21, 2020

Record last verified: 2010-01

Locations

RU (2); GB (1)